ORGO

Organogenesis Holdings Inc

0.7555

Nov 02 • 3:59 PM ET -0.0126 (-1.64%)

0.7600

Aftermarket • 7:30 PM ET +0.0045 (0.60%)

Healthcare Drug Manufacturers - Specialty & Generic USA Micro NASD

Peers: MDXG ANIK IART RCEL SNN BVS SMTI VCEL SNWV CELU

| Held by: VTI IWM VXF VTWO IWN DFAT DFSV SCHA VHT DFMC

Scroll to Statements

Index	RUT
Market Cap	97.21M
Enterprise Value	257.18M
Income	-105.85M
Sales	457.45M
Book/sh	1.15
Cash/sh	0.36
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	854
IPO	Jan 05, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	0.21
P/B	0.66
P/C	2.08
P/FCF	4.66
EV/EBITDA	31.21
EV/Sales	0.56
Quick Ratio	3.00
Current Ratio	3.52
Debt/Eq	0.23
LT Debt/Eq	0.20
Option/Short	Yes / Yes

EPS (ttm)	-0.83
EPS next Y	-0.31
EPS next Q	-0.17
EPS this Y	-575.08%
EPS next Y	77.45%
EPS next 5Y	-
EPS past 3/5Y	9.43% -0.14%
Sales past 3/5Y	7.76% 10.77%
EPS Y/Y TTM	-613.22%
Sales Y/Y TTM	6.50%
EPS Q/Q	-702.49%
Sales Q/Q	-56.68%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-103.91% -19.38%

Insider Own	44.68%
Insider Trans	0.00%
Inst Own	51.47%
Inst Trans	4.64%
ROA	-19.40%
ROE	-25.92%
ROIC	-24.34%
Gross Margin	63.15%
Oper. Margin	-5.40%
Profit Margin	-23.14%
SMA20	-27.98%
SMA50	-43.30%
SMA200	-67.93%
Trades

Shs Outstand	128.67M
Shs Float	71.18M
Short Float	21.90%
Short Ratio	18.64
Short Interest	15.59M
52W High	7.08 -89.32%
52W Low	0.76 -0.89%
Volatility	8.69% 7.63%
ATR (14)	0.08
RSI (14)	16.07
Beta	1.48
Rel Volume	2.72
Avg Volume	836.57K
Volume	2,279,010

Perf Week	-19.23%
Perf Month	-43.20%
Perf Quarter	-68.12%
Perf Half Y	-70.49%
Perf YTD	-85.42%
Perf Year	-82.22%
Perf 3Y	-67.44%
Perf 5Y	-93.13%
Perf 10Y	-
Recom	3.00
Target Price	2.00
Prev Close	0.77
Price	0.76
Change %	-1.64%

Consensus

Hold

Avg. Price Target

$2.00

Implied Upside

+164.7%

Analysts9incl. previous ratings

Rating Distribution5 Buy · 4 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 28, 2026	Initiated	TTruist	Hold	$3	+297.1%
May 08, 2026	Downgrade	BBTIG Research	Buy → Neutral
Jun 28, 2024	Initiated	LLake Street	Buy	$5	+561.8%
Feb 07, 2024	Initiated	CCantor Fitzgerald	Overweight	$5	+561.8%
Jun 15, 2023	Initiated	MMorgan Stanley	Equal-Weight	$5	+561.8%
May 24, 2023	Upgrade	BBTIG Research	Neutral → Buy	$10	+1,223.6%
Nov 10, 2022	Downgrade	BBTIG Research	Buy → Neutral
Aug 10, 2022	Downgrade	OOppenheimer	Outperform → Perform
Jan 10, 2020	Initiated	SSVB Leerink	Outperform	$9	+1,091.3%
Aug 26, 2019	Resumed	CCredit Suisse	Outperform	$9 → $10	+1,223.6%
May 02, 2019	Initiated	CCredit Suisse	Outperform	$9	+1,091.3%
Apr 17, 2019	Initiated	OOppenheimer	Outperform	$11	+1,356.0%
Apr 11, 2019	Initiated	SSunTrust	Buy	$11	+1,356.0%

Oct-12-26 04:10PM	Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPlyAM for Hard-to-Heal Diabetic Foot Ulcers (GlobeNewswire)
04:05PM	Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026 (GlobeNewswire)
Sep-21-26 05:06PM	These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch) +5.71%
Aug-06-26 05:22PM	Organogenesis: Q2 Earnings Snapshot (Associated Press) -22.82%
04:05PM	Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results (GlobeNewswire)
04:05PM	Loading…
Jul-27-26 04:05PM	Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity in the Most Challenging and Complex Venous Leg Ulcers (GlobeNewswire) +6.69%
Jul-09-26 07:30AM	Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 (GlobeNewswire)
Jul-06-26 04:05PM	Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu for the Management of Symptomatic Knee Osteoarthritis (GlobeNewswire) +5.08%
Jun-02-26 09:00AM	The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts (PR Newswire) -5.08%
May-07-26 05:49PM	Organogenesis: Q1 Earnings Snapshot (Associated Press) -6.32%
04:05PM	Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-28-26 04:30PM	Organogenesis Completes Rolling Submission of Biologics License Application for ReNu (GlobeNewswire)
Apr-06-26 07:02PM	Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPlyAM (GlobeNewswire)
05:30PM	Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu for Knee Osteoarthritis Pain (GlobeNewswire)
07:30AM	Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026 (GlobeNewswire)
01:12AM	Loading…
Feb-27-26 01:12AM	Organogenesis Q4 Earnings Call Highlights (MarketBeat) -13.24%
12:02AM	Organogenesis Holdings Inc (ORGO) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid ... (GuruFocus.com)
Feb-26-26 05:58PM	Organogenesis: Q4 Earnings Snapshot (Associated Press Finance) -9.98%
04:05PM	Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue (GlobeNewswire)
Feb-19-26 04:05PM	Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Dec-23-25 04:05PM	Organogenesis Announces Initiation of Biologics License Application for ReNu (GlobeNewswire)
Dec-15-25 04:25PM	Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu for Knee Osteoarthritis Pain (GlobeNewswire) +7.04%
Nov-07-25 12:10AM	Organogenesis Holdings Inc (ORGO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +44.73%
Nov-06-25 04:26PM	Organogenesis: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance (GlobeNewswire)
Nov-03-25 01:10PM	Organogenesis Applauds CMS's Significant Step In Payment Reform (GlobeNewswire) -5.88%
Oct-31-25 04:05PM	Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-25 04:05PM	Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Sep-26-25 11:24AM	Why Is Organogenesis Stock Trading Lower Friday? (Benzinga) -12.39%
Sep-25-25 04:50PM	Organogenesis Provides Update on Second Phase 3 ReNu Study (GlobeNewswire)
04:05PM	Loading…
Aug-27-25 04:05PM	Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September (GlobeNewswire) +5.79%
Aug-08-25 03:41AM	Organogenesis Holdings Inc (ORGO) Q2 2025 Earnings Call Highlights: Navigating Market ... (GuruFocus.com)
Aug-07-25 05:49PM	Organogenesis: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-22-25 04:05PM	Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025 (GlobeNewswire) +5.70%
Jul-15-25 09:00AM	Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation (GlobeNewswire) -10.24%
Jul-14-25 05:22PM	MiMedx and Organogenesis stocks tumble after CMS proposal to slash spending (Investing.com)
May-09-25 03:51AM	Organogenesis Holdings Inc (ORGO) Q1 2025 Earnings Call Highlights: Navigating Market ... (GuruFocus.com) -42.70%
May-08-25 06:05PM	Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:57PM	Organogenesis: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 10:41AM	Organogenesis Holdings Inc (ORGO) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-11-25 04:05PM	Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness (GlobeNewswire) +13.60%
Apr-07-25 04:05PM	Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Feb-28-25 11:14AM	Q4 2024 Organogenesis Holdings Inc Earnings Call (Thomson Reuters StreetEvents) +102.28%
02:42AM	Organogenesis Holdings Inc (ORGO) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:45AM	Organogenesis (ORGO) Q4 2024 Earnings Call Transcript (Motley Fool)
Feb-27-25 05:32PM	Organogenesis: Q4 Earnings Snapshot (Associated Press Finance) -5.54%
04:05PM	Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results (GlobeNewswire)
Feb-26-25 08:09AM	What To Expect From Organogenesis Holdings Inc (ORGO) Q4 2024 Earnings (GuruFocus.com)
Jan-27-25 07:30AM	Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025 (GlobeNewswire) +5.06%
Nov-22-24 04:05PM	Organogenesis Expands Manufacturing Capacity to Support Future Growth (GlobeNewswire)
Nov-15-24 09:25AM	Organogenesis Commends Final LCDs (GlobeNewswire)
Nov-13-24 02:23AM	Organogenesis Holdings Inc (ORGO) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com) +28.41%
Nov-12-24 09:45PM	Organogenesis (ORGO) Q3 2024 Earnings Call Transcript (Motley Fool)
05:40PM	Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:37PM	Organogenesis: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results (GlobeNewswire)
04:01PM	Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock (GlobeNewswire)
Nov-11-24 05:05PM	Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis (GlobeNewswire) +6.71%
Oct-16-24 07:30AM	Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Oct-01-24 04:05PM	Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers (GlobeNewswire)
Sep-04-24 04:05PM	Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-09-24 12:30AM	Organogenesis (ORGO) Q2 2024 Earnings Call Transcript (Motley Fool)
Aug-08-24 09:57PM	ORGO Stock Earnings: Organogenesis Hldgs Beats Revenue for Q2 2024 (InvestorPlace)
06:35PM	Organogenesis (ORGO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:24PM	Organogenesis: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
04:04PM	Organogenesis Shares ReNu Program Update (GlobeNewswire)
Jul-20-24 01:44AM	Organogenesis Holdings Inc. (ORGO): Is It Among the Best NASDAQ Penny Stocks to Invest In Now? (Insider Monkey)
Jul-15-24 04:05PM	Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024 (GlobeNewswire) +6.92%
Jun-06-24 04:05PM	Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference (GlobeNewswire)
May-10-24 03:09PM	Organogenesis Holdings Inc. Reports First Quarter 2024 Results: A Close Look at Financial ... (GuruFocus.com) +32.89%
12:07PM	Organogenesis Holdings Inc. (NASDAQ:ORGO) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:49AM	Q1 2024 Organogenesis Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-24 08:45PM	Organogenesis (ORGO) Q1 2024 Earnings Call Transcript (Motley Fool)
05:41PM	Organogenesis: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 07:00AM	Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis (GlobeNewswire)
Apr-16-24 07:30AM	Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-03-24 07:30AM	Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case (GlobeNewswire) +6.13%
Mar-02-24 08:39AM	Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 06:29PM	Why Organogenesis Holding Stock Plummeted by 18% Today (Motley Fool) -18.21%
Feb-29-24 05:45PM	Organogenesis (ORGO) Reports Break-Even Earnings for Q4 (Zacks)
04:50PM	Organogenesis: Q4 Earnings Snapshot (Associated Press Finance)
04:38PM	Organogenesis Holdings Inc (ORGO) Faces Revenue Decline in Q4 and FY 2023, Aims for Growth in 2024 (GuruFocus.com)
04:05PM	Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance (GlobeNewswire)
Feb-12-24 07:30AM	Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference (GlobeNewswire) +5.21%
Feb-08-24 04:05PM	Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Jan-15-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice (Zacks)
Dec-28-23 12:00PM	Organogenesis (ORGO) is a Great Momentum Stock: Should You Buy? (Zacks)
Dec-19-23 05:08AM	3 Biotech Stock Buys to Boost and Supercharge Portfolios (Entrepreneur: Stocks) +6.93%
Nov-11-23 09:30AM	Organogenesis Holdings Inc. (NASDAQ:ORGO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 06:47AM	Q3 2023 Organogenesis Holdings Inc Earnings Call (Thomson Reuters StreetEvents) +11.17%
Nov-09-23 07:45PM	Organogenesis (ORGO) Q3 2023 Earnings Call Transcript (Motley Fool)
05:41PM	Organogenesis: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leibowitz Arthur S	Director	Mar 09 '26	Buy	2.68	5,000	13,405	291,014	Mar 11 09:45 PM
Driscoll Michael Joseph	Director	Mar 09 '26	Buy	2.67	10,000	26,688	225,707	Mar 11 05:45 PM
NUSSDORF GLENN H	Director	Dec 16 '25	Sale	5.14	200,000	1,027,060	2,565,591	Dec 18 04:19 PM
Glenn Nussdorf	Director	Dec 16 '25	Proposed Sale	5.11	200,000	1,021,241		Dec 16 04:32 PM
NUSSDORF GLENN H	Director	Nov 26 '25	Sale	5.29	187,957	994,293	2,765,591	Nov 26 06:24 PM
NUSSDORF GLENN H	Director	Nov 24 '25	Sale	5.34	100,000	534,000	2,965,591	Nov 26 06:24 PM
NUSSDORF GLENN H	Director	Nov 25 '25	Sale	5.30	12,043	63,828	2,953,548	Nov 26 06:24 PM
Glenn Nussdorf	Director	Nov 25 '25	Proposed Sale	5.40	200,000	1,080,000		Nov 25 04:56 PM
Glenn Nussdorf	Director	Nov 24 '25	Proposed Sale	5.34	100,000	534,379		Nov 24 03:44 PM

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

PresidentMr. Gary S. Gillheeney Sr.

Chief Financial OfficerMr. David C. Francisco

Chief Operating OfficerMr. Patrick Bilbo

Esq.Ms. Lori H. Freedman B.A.

Chief Commercial OfficerMr. Brian Grow

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ORGO

Organogenesis Holdings Inc

Upgrade your Finviz experience